Recent Advances in the Management of Polycystic Ovary Syndrome: A Review Article.
combined oral contraceptive pills
hyperandrogenism
lifestyle interventions
menstrual irregularity
pcos
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
13
06
2022
accepted:
04
08
2022
entrez:
8
9
2022
pubmed:
9
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Polycystic ovarian syndrome (PCOS) is an endocrine disorder. This condition is characterized by chronic anovulation and ovarian dysfunction, unlike other ovulation disorders when the ovaries are non-functional or abnormal. Currently, most therapy is centred on the patient's primary complaint. Treatment focuses on reducing hyperandrogenism symptoms, restoring menstrual regularity, and achieving conception. In treating infertility caused by polycystic ovarian syndrome, letrozole (an aromatase inhibitor) appears to be more successful than clomiphene citrate (an anti-estrogen and a reference infertility drug). When provided by a multidisciplinary team, it can help patients maintain appropriate lifestyle changes, such as reducing body fat, increasing metabolism, and enhancing reproductive health. Compound oral contraceptives are the most common kind of androgen inhibitor and are the preferred therapy for menstrual disruption in PCOS patients who do not want to get pregnant. Weight loss should be prioritized for women with PCOS since a healthy, balanced diet combined with regular exercise can boost metabolism, increase insulin sensitivity, and aid weight loss safely. This will improve their physical health. Other than reproductive symptoms, PCOS symptoms include insulin resistance (IR), metabolic syndrome (MS), and chronic low-grade inflammation. Our understanding of the pathophysiological process, diagnosis, and therapy of PCOS has advanced recently.
Identifiants
pubmed: 36072214
doi: 10.7759/cureus.27689
pmc: PMC9440853
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e27689Informations de copyright
Copyright © 2022, Akre et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Reprod Biol Endocrinol. 2016 Jul 16;14(1):38
pubmed: 27423183
Hum Reprod. 2019 Feb 1;34(2):388
pubmed: 30521039
P T. 2013 Jun;38(6):336-55
pubmed: 23946629
N Engl J Med. 2016 Jul 7;375(1):54-64
pubmed: 27406348
Porto Biomed J. 2021 Jan 26;6(1):e116
pubmed: 33532657
Evid Based Complement Alternat Med. 2021 Feb 26;2021:5555315
pubmed: 33727939
J Endocrinol Invest. 2017 May;40(5):487-497
pubmed: 27838846
Ther Adv Endocrinol Metab. 2020 Jul 6;11:2042018820938305
pubmed: 32670541
Hum Reprod Update. 2014 Sep-Oct;20(5):748-58
pubmed: 24688118
Open Access J Contracept. 2017 Feb 02;8:13-23
pubmed: 29386951
Pediatrics. 2020 May;145(Suppl 2):S210-S218
pubmed: 32358213
J Obstet Gynaecol India. 2018 Oct;68(5):336-343
pubmed: 30224835
Comput Math Methods Med. 2021 Apr 15;2021:5587412
pubmed: 33953792
PLoS Genet. 2018 Dec 19;14(12):e1007813
pubmed: 30566500
Fertil Steril. 2021 Jan;115(1):92-93
pubmed: 32988616
Reprod Biol Endocrinol. 2014 Jan 03;12:3
pubmed: 24387273
J Obstet Gynaecol Can. 2010 May;32(5):495-502
pubmed: 20500959
Ther Adv Endocrinol Metab. 2018 Apr;9(4):123-134
pubmed: 29619209
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Hum Reprod. 2017 Feb;32(2):261-264
pubmed: 28119448